CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 EUR | +6.35% |
|
-1.33% | -14.10% |
| 04-04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
| Sales 2022 | - | Sales 2023 | 102K 109K 8.73M | Capitalization | 16.16M 17.28M 1.38B |
|---|---|---|---|---|---|
| Net income 2022 | -40M -42.77M -3.42B | Net income 2023 | -8M -8.55M -685M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.03M 1.04B | Net cash position 2023 | 5.95M 6.36M 509M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | +6.35% | ||
| 1 week | -1.33% | ||
| Current month | -4.56% | ||
| 1 month | -5.63% | ||
| 3 months | -25.39% | ||
| 6 months | -44.35% | ||
| Current year | -14.10% |
1 week
0.31
0.34
1 month
0.300.38
Current year
0.300.47
1 year
0.301.28
3 years
0.306.02
5 years
0.3018.90
10 years
0.3070.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 23/07/07 |
David Georges
DFI | Director of Finance/CFO | - | 31/12/18 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 23/07/07 |
Hilde Windels
CHM | Chairman | 59 | 06/05/18 |
Serge Goblet
BRD | Director/Board Member | - | 31/12/07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.335 | +6.35% | 17,101 |
| 25/04/24 | 0.315 | -1.56% | 1,939 |
| 24/04/24 | 0.32 | -3.03% | 9,263 |
| 23/04/24 | 0.33 | +3.13% | 19,412 |
| 22/04/24 | 0.32 | -5.74% | 7,803 |
Real-time Euronext Bruxelles, April 26, 2024 at 04:35 pm
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 14.82M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CYAD Stock
